<DOC>
	<DOCNO>NCT01121549</DOCNO>
	<brief_summary>The IES study ( A5991012 ) investigate 4742 patient treat 2 3 year tamoxifen , either continue treatment switch Aromasin速 total treatment period 5 year . Only 65 Romanian patient enrol IES study . It would therefore appear essential evaluate confirm tolerability Aromasin速 way use broad sample patient standard condition use stipulate MA . This Non-Interventional study design address issue .</brief_summary>
	<brief_title>A Non-Interventional Study With Aromasin速 As Adjuvant Treatment Of Invasive Early Breast Cancer</brief_title>
	<detailed_description>This prospective , non-comparative , non interventional study ( NIS ) four hundred ( 400 ) postmenopausal woman hormone-receptor positive invasive early breast cancer , follow 2-3 year initial adjuvant tamoxifen therapy conduct 60 site Romania accord protocol A5991091.The selection patient base diagnosis , attribution medicinal product follow-up subject fall within current medical practice . A Non-Interventional study primarily observational nature . The present Non-interventional Study perform medical oncologist medical oncologist /radiation oncologist agree take part project . n/a The study prematurely terminate August 31th 2012 due unexpected high rate patient withdrawal cause Aromasin reimbursement policy change Romania ; There safety issue relate study termination .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Postmenopausal female , define one next : 1 . Natural menopause &gt; /=1 year , 2 . Surgical ovariectomy , 3 . Chemotherapyinduced amenorrhoea &gt; /=2 year . Patients surgical treatment histological confirm breast cancer nonmetastatic time initial diagnosis . Patients diseasefree 2 3 year adjuvant tamoxifen treatment . Patients whose tumour estrogen receptor positive ( ER+ ) . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect study . Patients Aromasin速 treatment contraindicate ( see SmPC ) . Presence metastasis contra lateral tumour . Other adjuvant endocrine therapy . Another concomitant antineoplastic treatment Participation clinical trial investigational drug 30 day prior enrolment study . The patient suppose participate trial study period .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Prospective</keyword>
	<keyword>non-comparative</keyword>
	<keyword>NIS</keyword>
	<keyword>600</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>hormone-receptor</keyword>
	<keyword>positive</keyword>
	<keyword>EBC</keyword>
	<keyword>tamoxifen</keyword>
	<keyword>current medical practice .</keyword>
</DOC>